Company intelligence / Profile preview

BioGeneriX AG

Mannheim, Baden-Württemberg, Germany

Ownership: Private
Employees: ~2
Development stage: Phase 1

Overview

BioGeneriX AG, founded in Germany in June 2000, specializes in the preclinical and clinical development of biosimilars. The company has sponsored or collaborated on at least seventeen clinical trials, including multiple completed Phase III studies for biosimilar products such as XM22 (pegfilgrastim) and XM17 (recombinant FSH). It operates as a division of Teva Pharmaceuticals and focuses on developing biopharmaceutical drugs with known modes of action targeting established drug markets. Clinical results indicate successful completion of pivotal studies supporting regulatory filings for their lead programs.

Therapeutic areas: OncologyWomen's Health
Modalities: Biosimilars (recombinant proteins, therapeutic antibodies)
Industry: Biotech

Drug pipeline

1 asset

GlycoPEG-GCSF

Phase 1

Indications: Neutropenia

Partnerships

Asset purchase from Neose Technologies Inc.Collaborations with multinational clinical sites for trials.

Beyond the preview

Go deeper on BioGeneriX AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGeneriX AG.

Explore the full profile